Restructuring, Impairment, and Related Charges, Net (Tables)

9 Months Ended

Dec. 31, 2023

Restructuring and Related Activities [Abstract]

Restructuring, Impairment, and Related Costs

Restructuring, impairment, and related charges, net for the three months ended December 31, 2023 and 2022 consisted of the following:

	Three Months Ended December 31, 2023
(In millions)	U.S. Pharmaceutical		Prescription Technology Solutions (1)		Medical-Surgical Solutions		International		Corporate		Total
Severance and employee-related costs, net	$	(6)	$	1	$	—	$	—	$	(2)	$	(7)
Exit and other-related costs (2)	1		1		3		—		6		11
Asset impairments and accelerated depreciation	—		—		—		—		—		—
Total	$	(5)	$	2	$	3	$	—	$	4	$	4

(1)Includes costs related to operational efficiencies and cost optimization efforts described above to support the Company’s technology solutions.

(2)Exit and other-related costs consist of accruals for costs to be incurred without future economic benefits, project consulting fees, and other exit costs expensed as incurred.

	Three Months Ended December 31, 2022
(In millions)	U.S. Pharmaceutical		Prescription Technology Solutions		Medical-Surgical Solutions		International		Corporate		Total
Severance and employee-related costs, net	$	—	$	—	$	—	$	—	$	4	$	4
Exit and other-related costs (1)	1		1		1		7		15		25
Asset impairments and accelerated depreciation	1		—		—		1		—		2
Total	$	2	$	1	$	1	$	8	$	19	$	31

(1)Exit and other-related costs consist of accruals for costs to be incurred without future economic benefits, project consulting fees, and other exit costs expensed as incurred. Corporate includes costs for business transformation and optimization efforts related to the Company’s technology organization. The International segment includes costs related to the Company’s European divestitures.

Restructuring, impairment, and related charges, net, for the nine months ended December 31, 2023 and 2022 consisted of the following:

	Nine Months Ended December 31, 2023
(In millions)	U.S. Pharmaceutical		Prescription Technology Solutions (1)		Medical-Surgical Solutions		International		Corporate (1)		Total
Severance and employee-related costs, net	$	3	$	1	$	—	$	2	$	(1)	$	5
Exit and other-related costs (2)	3		6		9		9		24		51
Asset impairments and accelerated depreciation	—		—		—		1		27		28
Total	$	6	$	7	$	9	$	12	$	50	$	84

(1)Includes costs related to operational efficiencies and cost optimization efforts described above to support the Company’s technology solutions.

(2)Exit and other-related costs consist of accruals for costs to be incurred without future economic benefits, project consulting fees, and other exit costs expensed as incurred.

	Nine Months Ended December 31, 2022
(In millions)	U.S. Pharmaceutical		Prescription Technology Solutions		Medical-Surgical Solutions		International		Corporate		Total
Severance and employee-related costs, net	$	3	$	—	$	—	$	2	$	(2)	$	3
Exit and other-related costs (1)	2		4		3		15		44		68
Asset impairments and accelerated depreciation	4		11		—		2		(4)		13
Total	$	9	$	15	$	3	$	19	$	38	$	84

(1)Exit and other-related costs consist of accruals for costs to be incurred without future economic benefits, project consulting fees, and other exit costs expensed as incurred. Corporate includes costs for business transformation and optimization efforts related to the Company’s technology organization. The International segment includes costs related to the Company’s European divestitures.

Schedule of Restructuring and Asset Impairment Charges

The following table summarizes the activity related to the liabilities associated with the Company’s restructuring initiatives for the nine months ended December 31, 2023:

(In millions)	U.S. Pharmaceutical		Prescription Technology Solutions		Medical-Surgical Solutions		International		Corporate		Total
Balance, March 31, 2023 (1)	$	15	$	26	$	3	$	13	$	35	$	92
Restructuring, impairment, and related charges, net	6		7		9		12		50		84
Non-cash charges	—		—		—		(1)		(27)		(28)
Cash payments	(14)		(28)		(10)		(4)		(33)		(89)
Other (2)	5		—		—		(10)		—		(5)
Balance, December 31, 2023 (3)	$	12	$	5	$	2	$	10	$	25	$	54

(1)As of March 31, 2023, the total reserve balance was $92 million, of which $66 million was recorded in “Other accrued liabilities” and $26 million was recorded in “Other non-current liabilities” in the Company’s Condensed Consolidated Balance Sheet.

(2)Other primarily includes cumulative translation adjustments and transfers to certain other liabilities.

(3)As of December 31, 2023, the total reserve balance was $54 million, of which $21 million was recorded in “Other accrued liabilities” and $33 million was recorded in “Other non-current liabilities” in the Company’s Condensed Consolidated Balance Sheet.